Latest Hurler Syndrome Stories
ReportsnReports.com adds “Mucopolysaccharidosis I and II (MPS I & II) (Hurler Syndrome) - Pipeline Review, H2 2014” to its store.
Strengthens Leadership Position in Treatments for Hunter syndrome and Commitment to MPS II Patient Community LEXINGTON, Massachusetts, July 23, 2014 /PRNewswire/ --
ArmaGen to Receive up to Approximately $225 Million Including Initial Upfront Payment of $15 Million in Cash and Equity, an Additional Equity Investment, R&D Funding, Development and Sales Milestones,
- MPS IV A patients and families urge swift, publicly funded access to life-altering drug VIMIZIM(TM) - VANCOUVER, July 7, 2014 /CNW/ - The Canadian Society for Mucopolysaccharide
Approval delivers first pharmaceutical therapy for children and adults with ultra-rare, life-limiting disorder TORONTO, July 7, 2014 /CNW/ - BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. is a company focused on developing and commercializing biopharmaceuticals for serious diseases and other medical conditions.